A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

NCT04594798 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

DLBCL
Lymphoma, B-Cell

Interventions

DRUG: Polatuzumab vedotin
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone

Sponsor

University of Rochester

Collaborators

[object Object]